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Background: Although global hypomethylation of leukocyte DNA has been associated with an increased risk of
several sites of cancer, including breast cancer, determinants of global methylation level among healthy individuals
remain largely unexplored. Here, we examined whether postmenopausal endogenous sex hormones were
associated with the global methylation level of leukocyte DNA.
Methods: A cross-sectional study was conducted using the control group of a breast cancer case–control study in
Nagano, Japan. Subjects were postmenopausal women aged 55 years or over who provided blood samples. We
measured global methylation level of peripheral blood leukocyte DNA by luminometric methylation assay; estradiol,
estrone, androstenedione, dehydroepiandrosterone sulfate, testosterone and free testosterone by
radioimmunoassay; bioavailable estradiol by the ammonium sulfate precipitation method; and sex-hormone
binding globulin by immunoradiometric assay. A linear trend of association between methylation and hormone
levels was evaluated by regression coefficients in a multivariable liner regression model. A total of 185 women were
included in the analyses.
Results: Mean global methylation level (standard deviation) was 70.3% (3.1) and range was from 60.3% to 79.2%.
Global methylation level decreased 0.27% per quartile category for estradiol and 0.39% per quartile category for
estrone while it increased 0.41% per quartile category for bioavailable estradiol. However, we found no statistically
significant association of any sex hormone level measured in the present study with global methylation level of
leukocyte DNA.
Conclusions: Our findings suggest that endogenous sex hormones are not major determinants of the global
methylation level of leukocyte DNA.
Keywords: Cross-sectional study, Endogenous sex hormones, Global methylation level, Luminometric methylation
assay, Peripheral blood leukocyte DNABackground
DNA methylation, which is one type of epigenetic
change, may play an important role in carcinogenesis by
silencing tumor suppressor genes through hypermethyla-
tion or by activating oncogenes through hypomethyla-
tion [1]. In addition to gene-specific DNA methylation,* Correspondence: moiwasak@ncc.go.jp
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reproduction in any medium, provided the orglobal DNA hypomethylation in regions that are nor-
mally methylated, such as repeats or transposable ele-
ments, can also lead to genomic instability and altered
gene transcription, and thereby affect the normal growth
and differentiation of target tissues [1,2]. Although the
majority of methylation studies to date have focused on
localized hypomethylation and hypermethylation of spe-
cific genes in tumors [3,4], several epidemiological stud-
ies have examined the global methylation level of
peripheral blood DNA, which is considered a potential
surrogate biomarker for systemic genome methylationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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leukocyte DNA has been associated with an increased
risk of several sites of cancer, including breast cancer
[5,6,8]. However, determinants of global methylation
level among healthy individuals have remained largely
unexplored, although a number of genetic and environ-
mental factors are thought to influence the level of DNA
methylation [10].
Given that global hypomethylation has been associated
with an increased risk of breast cancer [8], as well as the
important role of endogenous sex hormones in the eti-
ology of breast cancer, particularly estrogens [11-13], we
hypothesized that endogenous sex hormone level might
be a determinant of the global methylation level of
leukocyte DNA. Clarification of the association between
sex hormones and global DNA methylation level may
contribute to a better understanding of the etiology of
breast cancer.
In the present study, we tested the hypothesis based




Subjects were postmenopausal women who participated
as controls in a multicenter, hospital-based case–control
study of breast cancer conducted from May 2001 to Sep-
tember 2005 at four hospitals in Nagano Prefecture,
Japan. Details of this study have been described previ-
ously [14,15]. The study protocol was approved by the
institutional review board of the National Cancer Center,
Tokyo, Japan.
Briefly, the case subjects were a consecutive series of
women aged 20–74 years with newly diagnosed, histolo-
gically confirmed invasive breast cancer who were ad-
mitted to one of the four hospitals during the survey
period. Of the 412 eligible patients, 405 (98%) agreed to
participate. Healthy controls were selected from medical
checkup examinees at two of the hospitals and con-
firmed to not have any cancer. They were matched with
one case subject each by age (within three years) and
residential area during the study period. Among poten-
tial control women, one declined to participate and two
refused to provide blood samples. Consequently, written
informed consent was obtained from 405 matched pairs.
Of 405 control women, we selected postmenopausal
women aged over 55 years who provided blood samples
and reported an energy intake between 500 and
4000 kcal. The present study included a total of 185
women.
Data collection
Participants were asked to complete a self-administered
questionnaire which included questions on demographiccharacteristics, anthropometric factors, smoking habit,
family history of cancer, physical activity, medical his-
tory, and menstrual and reproductive history. Dietary
habits were investigated using a 136-item semi-
quantitative food-frequency questionnaire (FFQ) which
was developed and validated in a Japanese population
[16,17]. In the FFQ, participants were questioned on
how often they consumed individual food items (fre-
quency of consumption), as well as relative sizes com-
pared to standard portions. Daily food intake was
calculated by multiplying frequency by standard portion
and relative size for each food item in the FFQ. Daily
intakes of nutrients were calculated using the fifth
revised and enlarged edition of the Standard Tables of
Food Composition in Japan [18]. The FFQ included
questions on supplement use, but nutrient intake from
supplements was not included in the analyses because
no comprehensive database for supplements was avail-
able. Any influence is assumed to be minimal, however,
because none of the present subjects used folate supple-
mentation and only eight subjects (4.3%) used vitamin B
supplementation. We previously documented that the
questionnaire’s assessments of folate intake, and vitamin
B2, B6, and B12 intake were reasonably valid [14,17].
Participants provided blood samples at the time they
returned their self-administered questionnaire. Whole
blood in 7-mL EDTA-2Na vacutainers and serum sam-
ples were stored at −80°C until analysis.
Laboratory analysis
Details of hormone assays have been described previ-
ously [19]. Briefly, we measured estradiol, estrone,
androstenedione, dehydroepiandrosterone sulfate
(DHEAS), testosterone, and free testosterone in serum
by radioimmunoassay. Bioavailable estradiol (free and
albumin-bound estradiol) was measured by the ammo-
nium sulfate precipitation method. Sex-hormone binding
globulin (SHBG) was measured by immunoradiometric
assay. Lower detection limits (LODs) were 5 pg/mL for
estradiol, 15 pg/mL for estrone, 6.25 nmol/L for SHBG,
0.1 ng/mL for androstenedione, 5 ug/dL for DHEAS,
0.05 ng/mL for testosterone, and 0.4 pg/mL for free tes-
tosterone. Measurement values below the LOD were
assigned half the value of the LOD if measurable values
below the LOD were not available. Intra-assay coeffi-
cients of variation (CV) were 6.5% for estradiol at a
mean concentration of 24.9 pg/mL (n = 12), 10.6% for
bioavailable estradiol at a mean level of 48.1% (n = 10),
5.6% for estrone at a mean concentration of 101.7 pg/
mL (n = 10), 4.7% for SHBG at a mean concentration of
104.6 nmol/L (n = 10), 9.4% for androstenedione at a
mean concentration of 1.33 ng/mL (n = 10), 5.2% for
DHEAS at mean concentration of 75 ug/dL (n = 10),
4.5% for testosterone at a mean concentration of
Table 1 Characteristics of the study population
Mean Standard
deviation
Age (years) 62.8 5.7
Height (cm) 152.9 5.5
Body mass index (kg/m2) 23.4 2.9
Age at menarche (years) 13.9 1.6
Age at menopause (years) 50.0 3.8
Age at first birth (years)* 26.2 3.3
Number %
Family history of breast cancer, n (%) 17 9.2
History of benign breast disease, n (%) 11 6.0
Nulliparous, n (%) 17 9.2
Number of births (4 or more births), n (%)* 6 3.6
Breast feeding (yes), n (%)* 154 93.3
Smoking (ever smoker), n (%) 6 3.3
Alcohol drinking (drinker), n (%) 67 36.2
Physical activity in past 5 years (yes), n (%) 85 46.5
*Among parous women only.
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mean concentration of 5.4 pg/mL (n = 10). A commercial
laboratory performed all hormone assays and provided
information on intra-assay CVs (Mitsubishi Kagaku Bio-
Clinical Laboratories, Tokyo, Japan).
Genomic DNA was extracted from the peripheral
blood using a Qiagen FlexiGene DNA Kit (Qiagen, Hil-
den, Germany) according to the manufacturer’s protocol.
Global DNA methylation was quantified by LUMA
(LUminometric Methylation Assay) [20,21]. Three hun-
dred nanograms of Genomic DNA were cleaved with
HapII + EcoRI or MspI + EcoRI in two separate 20-μl
reactions containing 2 μl of 10 ×T buffer (330 mM Tris-
acetate, 100 mM Mg-acetate, 660 mM K-acetate, 5 mM
dithiothreitol), 2 μl of 0.1% BSA, and 5 units of each of
the restriction enzymes. The reactions were set up in a
PSQ 96 Plate Low (Qiagen) and incubated at 37°C for
1 h. Then, 20 μl of annealing buffer that contained
200 mM Tris-acetate and 50 mM Mg-acetate pH 7.6
was added to the cleavage reactions, and samples were
assayed using PSQ96 MA system (Biotage AB, Uppsala,
Sweden). The instrument was programmed to add
dNTPs in six steps, including Step 1, dATPαS; Step 2,
mixture of dGTP+ dCTP; Step 3, dTTP; Step 4, mixture
of dGTP+dCTP; Step 5, water; and Step 6, dATP. Peak
heights were calculated using the PSQ96 MA software.
HapII/EcoRI and MspI/EcoRI ratios were calculated as
(dGTP+ dCTP)/dATP for each reaction. The HapII/
MspI ratio was then calculated as (HapII/EcoRI)/(MspI/
EcoRI), which corresponds to the proportion of
unmethylated CCGG. Restriction enzymes (HapII, MspI,
and EcoRI) were purchased from Takara Bio (1053A,
1150A and 1040A, respectively; Shiga, Japan). PyroMark
Gold Q96 Reagents for pyrosequencing were purchased
from Qiagen (972804). DNA quantification was per-
formed using the Quan-iT PicoGreen dsDNA Reagent
and kit (P7581, Invitrogen, CA, USA). Intra-assay CV
was 6.4% at a mean level of 74% (n = 20).
Five polymorphisms in methylenetetrahydrofolate re-
ductase (MTHFR) (rs1801133 and rs1801131), methio-
nine synthase (MTR) (rs1805087), and methionine
synthase reductase (MTRR) (rs10380 and rs162049) were
genotyped by TaqMan SNP Genotyping Assays devel-
oped by Applied Biosystems (Foster City, CA). Genotype
frequencies were tested for deviation from the Hardy–
Weinberg equilibrium with the χ2-test as quality control
for genotyping (all P values> 0.05).
Statistical analysis
Hormone levels were divided into median or quartile
categories. Adjusted mean global methylation levels of
leukocyte DNA according to endogenous sex hormone
levels were calculated using a multivariable liner regres-
sion model. To test linear trends for mean hormonelevels, regression coefficients (β) were calculated in the
multivariable linear regression model using median or
quartile categories of individual hormone levels as or-
dinal variables. We performed the initial analyses with
age-adjustment. In multivariate model, the following
variables were used for adjustment: age, family history of
breast cancer, history of benign breast disease, age at
menarche, age at menopause, number of births, age at
first birth, height, body mass index (BMI), smoking sta-
tus, alcohol drinking habit, physical activity in the past
five years, and energy-adjusted folate intake, most of
which are known as potential breast cancer risk factors
[11,12]. Dietary folate intake was adjusted for total en-
ergy intake with the use of the residual method [22,23].
To investigate potential effect modification, subgroup
analyses were performed by dietary and genetic factors
related to one-carbon metabolism and tests for inter-
action were carried out. All P values reported are two-
sided, and significance level was set at P< 0.05. All
statistical analyses were performed with SAS software
version 9.1 (SAS Institute, Inc., Cary, NC).
Results
Mean age (standard deviation [SD]) among the total of
185 women was 62.8 (5.7) years old and mean BMI (SD)
was 23.4 (2.9) (Table 1). Measurement of global methyla-
tion levels of leukocyte DNA and endogenous sex hor-
mone levels was completed in 185 women. Mean global
methylation level (SD) was 70.3% (3.1) and range was
from 60.3% to 79.2% (Table 2). The proportion of women
with levels below the LOD were 1.6% for estradiol, 6.5%
for estrone, 0% for bioavailable estradiol and SHBG, 0.5%
Table 2 Distribution of global methylation level in
leukocyte DNA and endogenous sex hormone level








Global methylation level in leukocyte DNA (%)
70.3 3.1 70.2 (68.5, 72.3) 0 0
Estradiol (pg/mL)
9.7 5.7 9.0 (7.7, 10.4) 3 1.6
Bioavailable estradiol (%)
24.2 7.0 23.0 (18.7, 28.9) 0 0
Estrone (pg/mL)
24.4 9.5 24.0 (18.0, 28.0) 12 6.5
Sex hormone binding globulin (nmol/L)
80.4 35.4 76.3 (57.0, 97.4) 0 0
Androstenedione (ng/mL)
0.73 0.31 0.70 (0.50, 1.00) 1 0.54
Dehydroepiandrosterone sulfate (DHEAS) (ug/dL)
59.8 32.1 54.0 (38.0, 76.0) 1 0.54
Testosterone (ng/mL)
0.07 0.08 0.07 (Not detected,
0.11)
76 41.1
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and 95% for free testosterone. Because of the high per-
centage of women with levels below the LOD, we did not
use free testosterone in the present analyses. Women with
estrone values> 125 pg/mL, estradiol values> 75 pg/mL,
or testosterone values> 125 ng/dL are suspected to use
postmenopausal hormones but none of our present
women met the above conditions.
Mean global methylation levels according to endo-
genous sex hormone levels are shown in Table 3 and
Figure 1. In the age-adjusted model, a higher level of
estrone was significantly associated with a lower level of
global methylation (0.45% decrease per quartile category,
p = 0.03) but no statistically significant association was
observed for other sex hormones (data not shown in
Table). In the multivariate model we did not find a sta-
tistically significant association between any sex hor-
mone level measured in the present study and the global
methylation level of leukocyte DNA. However, higher
levels of estradiol, estrone, androstenedione, DHEAS,
and testosterone were associated with a lower level of
global methylation while a higher bioavailable estradiol
level was associated with a higher level of global methy-
lation. Global methylation level decreased 0.27% per
quartile category for estradiol (p = 0.20) and 0.39% per
quartile category for estrone (p = 0.06) while it increased
0.41% per quartile category for bioavailable estradiol(p = 0.06). We further calculated regression coefficients
per unit using a continuous variable of individual natural
log-transformed hormone levels. The borderline statisti-
cally significant associations for estrone and bioavailable
estradiol disappeared (p = 0.15 for estrone and p = 0.20
for bioavailable estradiol) and none of the associations
were statistically significant (data not shown in Table).
We performed subgroup analyses of associations be-
tween sex hormone level and global methylation level by
alcohol drinking status and folate intake (Table 4). A
higher DHEAS level was significantly associated with a
lower level of global methylation among alcohol-
drinking women (0.78% decrease per quartile category),
whereas no association was observed among non-
drinkers (0.11% increase per quartile category) (P for
interaction = 0.03). No statistically significant interaction
was observed for other sex hormones, however. We fur-
ther performed subgroup analyses by vitamin B2, B6,
and B12, and five polymorphisms in MTHFR, MTR, and
MTRR but found no statistically significant interaction
(data not shown).
Discussion
In this cross-sectional study among postmenopausal
Japanese women, we found no statistically significant as-
sociation between endogenous sex hormone level and
the global methylation level of peripheral blood
leukocyte DNA. To our knowledge, this is the first study
to test the hypothesis that endogenous sex hormones are
potential determinants of the global methylation level of
leukocyte DNA. Our findings did not support this hy-
pothesis, however, and suggest that endogenous sex hor-
mones might not be major determinants.
Many epidemiological studies have confirmed the im-
portant role of endogenous sex hormones, particularly
estrogens, in the etiology of breast cancer [11,12]. A
pooled analysis of nine prospective studies showed that
higher estrogens and their androgen precursors were
associated with a higher risk of breast cancer in postme-
nopausal women [13]. In addition, several well-known
risk factors have also implicated an etiologic role of sex
hormones, including age at menarche and menopause,
parity and age at first birth, and BMI [11]. Recently,
Choi et al.. reported that global hypomethylation was
associated with an increased risk of breast cancer [8],
suggesting that the global methylation level of leukocyte
DNA plays a role in the etiology of breast cancer. How-
ever, our findings suggest that global methylation level
does not serve as a surrogate marker for the level of en-
dogenous sex hormones and that the mechanisms by
which global hypomethylation increases the risk of
breast cancer might involve non-hormonal factors.
Several possible explanations for the observed absence
of associations can be considered. First, misclassification










Lowest 6.8 45 70.3 71.0 (68.9, 73.1)
Second 8.2 45 70.8 71.5 (69.5, 73.4)
Third 9.7 47 70.6 71.2 (69.3, 73.1)
Highest 11.4 48 69.4 70.2 (68.2, 72.1)
Continuous (per quartile category) -0.27 (-0.68, 0.15) 0.20
Bioavailable estradiol (%)
Lowest 16.6 45 69.5 69.7 (67.6, 71.8)
Second 20.6 47 70.7 71.2 (69.3, 73.0)
Third 26.0 44 70.5 70.8 (68.8, 72.9)
Highest 32.5 49 70.4 71.2 (69.2, 73.2)
Continuous (per quartile category) 0.41 (-0.01, 0.84) 0.06
Estrone (pg/mL)
Lowest 15.0 38 70.6 71.6 (69.6, 73.7)
Second 21.0 54 70.6 71.8 (69.8, 73.7)
Third 25.5 40 70.8 71.8 (69.8, 73.9)
Highest 31.0 53 69.3 70.4 (68.6, 72.3)
Continuous (per quartile category) -0.39 (-0.80, 0.02) 0.06
Sex hormone binding globulin (nmol/L)
Lowest 44.1 46 69.9 70.9 (68.9, 72.8)
Second 67.1 46 70.5 71.6 (69.6, 73.6)
Third 84.9 45 70.8 71.7 (69.7, 73.7)
Highest 113.5 48 69.9 70.7 (68.8, 72.6)
Continuous (per quartile category) -0.05 (-0.47, 0.37) 0.81
Androstenedione (ng/mL)
Lowest 0.30 39 70.5 71.6 (69.5, 73.6)
Second 0.60 44 70.1 71.2 (69.2, 73.1)
Third 0.80 55 70.9 71.9 (69.9, 73.9)
Highest 1.10 47 69.5 70.5 (68.7, 72.4)
Continuous (per quartile category) -0.24 (-0.67, 0.19) 0.27
Dehydroepiandrosterone sulfate (DHEAS) (ug/dL)
Lowest 27.5 46 70.7 71.8 (69.7, 73.8)
Second 45.0 45 69.8 70.7 (68.8, 72.7)
Third 63.0 47 70.7 71.4 (69.5, 73.3)
Highest 95.0 47 69.9 70.8 (68.8, 72.8)
Continuous (per quartile category) -0.24 (-0.66, 0.18) 0.26
Testosterone (ng/mL)
Lowest 0.00 90 70.4 71.1 (69.3, 73.0)
Highest 0.11 95 70.1 71.0 (69.1, 72.8)
Continuous (per median category) -0.17 (-1.10, 0.77) 0.73
* Adjusted for age (continuous), family history of breast cancer (yes, no), history of benign breast disease (yes, no), age at menarche (continuous), age at
menopause (continuous), number of births (0, 1, 2-3, 4+), age at first birth (≤24, 25-26, ≥27, nulliparous), height (continuous), body mass index (continuous),
smoking (never smokers, ever smokers), alcohol drinking (non-drinkers, occasional drinkers, regular drinkers), physical activity in past 5 years (no, ≤2 days/week,
≥3 days/week), and energy-adjusted folate intake (continuous).
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Figure 1 Scatter plot between natural log-transformed estrone
level and global methylation levels of leukocyte DNA.
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true association. However, since the reproducibility of
assays for global methylation and sex hormone levels
were relatively high, with an intra-assay CV for global
methylation of 6.4%, and a range for hormones from
4.5% for testosterone to 10.6% for bioavailable estradiol,
the absence of associations was unlikely due to measure-
ment error. On the other hand, global methylation level
might be affected by differences in the proportion of
white blood cell types. Indeed, Zhu et al.. reported that
the proportion of neutrophils and lymphocytes among
white blood cell types modified LINE-1 methylation
levels measured in blood DNA [9]. In the present study,
since we measured global methylation level on white
blood cells by the LUMA method, the possibility of
measurement error due to different proportions of white
blood cell types cannot be excluded. Such misclassifica-
tion might accordingly have attenuated the true associ-
ation, which might in turn have explained our results, at
least in part. Second, the single time point measurement
of serum hormone levels might not have captured the
overall activity of the sex hormone-related signaling
pathway of the subject up to the age of study. Third, al-
though the present study included a total of 185 women,
it may not have had sufficient statistical power to detect
small associations.
Differences in assessment methods of global DNA
methylation require consideration. While several previ-
ous studies estimated global DNA methylation based on
data restricted to repetitive DNA elements, such as Alu
and LINE-1 [7,8], the present study used LUMA, which
allows the estimation of genome-wide DNA methylationlevels. Differences in assessment methods might there-
fore have affected study results. For example, Choi et al..
found that global hypomethylation of leukocyte DNA
measured by 5-methyldeoxycytosine (5-mdC) was asso-
ciated with an increased risk of breast cancer but saw no
association with the LINE-1 methylation level of leukocyte
DNA [8]. Similarly, Wischwendter et al. reported no asso-
ciation between the Alu methylation level of leukocyte
DNA and breast cancer risk [7].
The mechanisms by which endogenous sex hormone
levels might affect global methylation status have not been
elucidated. However, there is some evidence that estrogens
or endocrine disruptors might alter DNA methylation status
[24-26]. Studies in mice have shown that neonatal exposure
to diethylstilbestrol (DES), a synthetic non-steroidal estro-
gen, induced hypomethylation of estrogen-responsive lacto-
ferrin gene and proto-oncogene c-fos in utero [24,25].
Another study showed that exposure to persistent organic
pollutants such as polychlorinated biphenyls, many of which
are known endocrine disruptors, was associated with global
DNA hypomethylation in Greenlandic Inuit [26].
In our subjects, subgroup analyses suggested that alcohol
drinking modified the association between endogenous sex
hormone levels and the global methylation level of leukocyte
DNA: higher DHEAS was significantly associated with a
lower level of global methylation among alcohol drinkers,
whereas no association was observed among non-drinkers.
Since alcohol consumption interferes with folate metabolism
[27] and decreases levels of serum folate [28], our findings
might indicate that higher sex hormone levels were asso-
ciated with a lower level of global methylation among sub-
groups with a low folate status only. This hypothesis,
however, does not appear to be supported by our sub-
group analyses by folate intake or MTHFR polymorph-
isms (rs1801133 and rs1801131). Although the T allele of
MTHFR (rs1801133) and C allele of MTHFR (rs1801131)
have shown lower enzyme activity [29,30], no remarkable
difference in global methylation level was observed
among genotypes of MTHFR. These inconsistent findings
might be explained by multiple comparisons, insufficient
power, or the possibility that alcohol consumption inter-
acts with sex hormone levels via a mechanism other than
the folate-related metabolism. In any case, the findings
of our subgroup analyses should be interpreted with cau-
tion, and further research to clarify effect modification
by dietary and genetic factors related to one-carbon me-
tabolism on the association between sex hormone level
and global methylation level is clearly required.
Conclusions
In this cross-sectional study among postmenopausal
Japanese women, we found no statistically significant as-
sociation between endogenous sex hormones and the
global methylation level of leukocyte DNA. Although
Table 4 Subgroup analyses of association between mean global methylation level in leukocyte DNA and endogenous
sex hormone level by alcohol drinking status and folate intake
Multivariate-adjusted* Multivariate-adjusted* P for
interactionβ 95% confidence
interval
P value β 95% confidence
interval
P value
Alcohol drinking=Non-drinker Alcohol drinking=Drinker†
Estradiol (pg/mL)
-0.09 (-0.57, 0.39) 0.71 -0.52 (-1.37, 0.32) 0.22 0.16
Bioavailable estradiol (%)
0.49 (0.01, 0.97) 0.04 0.26 (-0.60, 1.13) 0.54 0.09
Estrone (pg/mL)
-0.28 (-0.77, 0.21) 0.26 -0.48 (-1.29, 0.33) 0.24 0.34
Sex hormone binding globulin (nmol/L)
-0.11 (-0.61, 0.38) 0.65 0.03 (-0.77, 0.83) 0.95 0.26
Androstenedione (ng/mL)
-0.23 (-0.74, 0.29) 0.39 -0.14 (-0.99, 0.70) 0.74 0.92
Dehydroepiandrosterone sulfate (DHEAS) (ug/dL)
0.11 (-0.41, 0.63) 0.67 -0.78 (-1.56, 0.001) 0.05 0.03
Testosterone (ng/mL)
-0.24 (-1.36, 0.88) 0.67 -0.20 (-1.95, 1.54) 0.81 0.44
Folate intake= Low{ Folate intake=High}
Estradiol (pg/mL)
-0.05 (-0.71, 0.61) 0.88 -0.38 (-0.94, 0.18) 0.18 0.79
Bioavailable estradiol (%)
0.64 (-0.02, 1.30) 0.06 0.26 (-0.37, 0.88) 0.42 0.47
Estrone (pg/mL)
-0.30 (-0.92, 0.32) 0.34 -0.35 (-0.94, 0.24) 0.25 0.93
Sex hormone binding globulin (nmol/L)
0.08 (-0.61, 0.77) 0.82 -0.12 (-0.73, 0.48) 0.69 0.74
Androstenedione (ng/mL)
-0.67 (-1.36, 0.02) 0.06 -0.04 (-0.60, 0.51) 0.88 0.07
Dehydroepiandrosterone sulfate (DHEAS) (ug/dL)
-0.45 (-1.07, 0.17) 0.15 -0.12 (-0.69, 0.46) 0.68 0.42
Testosterone (ng/mL)
-0.82 (-2.30, 0.65) 0.27 0.45 (-0.86, 1.76) 0.49 0.08
* Adjusted for age (continuous), family history of breast cancer (yes, no), history of benign breast disease (yes, no), age at menarche (continuous), age at
menopause (continuous), number of births (0, 1, 2-3, 4+), age at first birth (≤24, 25-26, ≥27, nulliparous), height (continuous), body mass index (continuous),
smoking (never smokers, ever smokers), alcohol drinking (non-drinkers, occasional drinkers, regular drinkers), physical activity in past 5 years (no, ≤2 days/week,
≥3 days/week), and energy-adjusted folate intake (continuous).
† Median consumption of ethanol = 48.3 g per week.
{ Median consumption of folate = 378.5 ug per day.
} Median consumption of folate = 578.1 ug per day.
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women, our findings suggest that endogenous sex hor-
mones might not be major determinants of the global
methylation level of leukocyte DNA and that mechan-
isms by which global hypomethylation increases the risk
of breast cancer might involve non-hormonal factors. A
comprehensive understanding of the determinants of theglobal methylation level of leukocyte DNA and the role
of this level in the etiology of breast cancer awaits fur-
ther study.
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